{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:59:32Z","timestamp":1783735172383,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Association pour la Recherche sur les Infections Virales (ARIV)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.antiviral.2014.08.014","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T13:14:33Z","timestamp":1409922873000},"page":"8-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism"],"prefix":"10.1016","volume":"111","author":[{"given":"L\u00e9a","family":"Pilorg\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Burrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Za\u00efna","family":"A\u00eft-Arkoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Agut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-4662","authenticated-orcid":false,"given":"David","family":"Boutolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.08.014_b0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/rmv.344","article-title":"Human cytomegalovirus terminase as a target for antiviral chemotherapy","volume":"12","author":"Bogner","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0010","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1128\/JVI.01967-07","article-title":"The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome","volume":"82","author":"Borst","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0015","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2008.11.003","article-title":"Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection","volume":"81","author":"Boutolleau","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.014_b0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2011.04.015","article-title":"Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir","volume":"91","author":"Boutolleau","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.014_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/135965350701200209","article-title":"New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modeling of the catalytic site DEXDc","volume":"12","author":"Champier","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2014.08.014_b0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/135965350801300504","article-title":"Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity","volume":"13","author":"Champier","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2014.08.014_b0115","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.08.014_b0120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.43.6.1500","article-title":"Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance","volume":"43","author":"Chou","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.014_b0050","doi-asserted-by":"crossref","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","article-title":"Interaction of the putative cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides","volume":"79","author":"Dittmer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0055","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1128\/AAC.48.5.1865-1868.2004","article-title":"Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between III and I","volume":"48","author":"Fillet","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.014_b0060","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.014_b0070","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2001","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2014.08.014_b0075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.78.2.710-715.2004","article-title":"Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides","volume":"78","author":"Komazin","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0080","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0085","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2014.08.014_b0090","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.014_b0095","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2014.08.014_b0100","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (Letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.014_b0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2014.08.014_b0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl. Int."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T11:06:28Z","timestamp":1650107188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214002514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":22,"alternative-id":["S0166354214002514"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.08.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}